TY - JOUR
T1 - Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer
T2 - defining treatment targets and dynamic changes during disease progression
AU - Klocker, Eva Valentina
AU - Hasenleithner, Samantha
AU - Bartsch, Rupert
AU - Gampenrieder, Simon P.
AU - Egle, Daniel
AU - Singer, Christian F.
AU - Rinnerthaler, Gabriel
AU - Hubalek, Michael
AU - Schmitz, Katja
AU - Bago-Horvath, Zsuzsanna
AU - Petzer, Andreas
AU - Heibl, Sonja
AU - Heitzer, Ellen
AU - Balic, Marija
AU - Gnant, Michael
N1 - Gampenrieder: Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Austria; Lehr-KH Barmherzige Schwestern, Elisabethinen, Ordensklinikum Linz GmbH, Austria
PY - 2024/6/12
Y1 - 2024/6/12
N2 - The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non-invasive nature of this approach allows for molecular profiling of the entire tumor entity, while also enabling real-time monitoring of the effectiveness of cancer therapies as well as the identification of resistance mechanisms to guide targeted therapy. Although the field of ctDNA studies offers a wide range of applications, including in early disease, in this review we mainly focus on the role of ctDNA in the dynamic molecular characterization of unresectable locally advanced and metastatic BC (mBC). Here, we provide clinical practice guidance for the rapidly evolving field of molecular profiling of mBC, outlining the current landscape of liquid biopsy applications and how to choose the right ctDNA assay. Additionally, we underline the importance of exploring the clinical relevance of novel molecular alterations that potentially represent therapeutic targets in mBC, along with mutations where targeted therapy is already approved. Finally, we present a potential roadmap for integrating ctDNA analysis into clinical practice.
AB - The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non-invasive nature of this approach allows for molecular profiling of the entire tumor entity, while also enabling real-time monitoring of the effectiveness of cancer therapies as well as the identification of resistance mechanisms to guide targeted therapy. Although the field of ctDNA studies offers a wide range of applications, including in early disease, in this review we mainly focus on the role of ctDNA in the dynamic molecular characterization of unresectable locally advanced and metastatic BC (mBC). Here, we provide clinical practice guidance for the rapidly evolving field of molecular profiling of mBC, outlining the current landscape of liquid biopsy applications and how to choose the right ctDNA assay. Additionally, we underline the importance of exploring the clinical relevance of novel molecular alterations that potentially represent therapeutic targets in mBC, along with mutations where targeted therapy is already approved. Finally, we present a potential roadmap for integrating ctDNA analysis into clinical practice.
KW - Breast cancer
KW - circulating tumor DNA
KW - Liquid biopsy
KW - Precision medicine
KW - Targeted therapies
KW - Therapeutic targets
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001245529500001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1002/1878-0261.13671
DO - 10.1002/1878-0261.13671
M3 - Review article
C2 - 38867388
SN - 1574-7891
JO - MOLECULAR ONCOLOGY
JF - MOLECULAR ONCOLOGY
ER -